Form 4: Collegium Pharmaceutical Executive Scott Dreyer Sells Shares Under 10b5-1 Plan

EVP & Chief Commercial Officer of Collegium Pharmaceutical, Scott Dreyer, sold shares of common stock on March 20 and 21, 2025, under a pre-arranged 10b5-1 trading plan.

Summary

• Scott Dreyer, EVP & Chief Commercial Officer of Collegium Pharmaceutical, sold shares of the company's common stock on March 20 and 21, 2025.
• The sales were executed under a Rule 10b5-1 trading plan adopted on August 28, 2024.
• On March 20, 2025, 1,927 shares were sold at a weighted average price of $30.0005, with prices ranging from $30.00 to $30.01.
• On March 21, 2025, 18,881 shares were sold at a weighted average price of $30.0293, with prices ranging from $30.00 to $30.48.
• Following these transactions, Dreyer directly owns 103,613 shares of Collegium Pharmaceutical common stock.

Sentiment

Score: 5

Explanation: The document is a routine SEC filing related to stock sales by an executive, which is neutral in sentiment.

Industry Context

Executive stock sales are a common occurrence and are often part of personal financial planning. The use of a 10b5-1 trading plan allows insiders to sell shares without being accused of trading on non-public information.

Stakeholder Impact

• The stock sales could have a minor impact on shareholders, potentially creating slight downward pressure on the stock price in the short term.

Key Dates

Keywords

Form 4, Scott Dreyer, Collegium Pharmaceutical, Stock Sale, 10b5-1 Trading Plan, Executive, Shares